PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

SGLT2i Plus GLP-1 RA: No Clear MACE or Kidney Gain Over Monotherapy

Endocrinology / Diabetes / Obesity

Background Information

Combining the two classes lowered heart failure admissions but not MACE or major kidney events.

Combined SGLT2 inhibitor plus GLP-1 RA therapy is widely recommended, but randomized evidence that it beats either class alone is thin. In a network meta-analysis of 12 RCTs (99,683 participants), combination therapy did not significantly reduce MACE versus SGLT2i (RR 0.86, 95% CI 0.74-1.01) or GLP-1 RA (RR 0.95, 0.81-1.12), or major adverse kidney events versus SGLT2i (RR 1.05, 0.74-1.49) or GLP-1 RA (RR 0.86, 0.60-1.21). Heart failure admissions were lower than with SGLT2i (RR 0.72, 0.52-0.99) or GLP-1 RA (RR 0.62, 0.45-0.86). All estimates were very low certainty and indirect, since no trial randomized patients to combination versus monotherapy. Combination therapy is reasonable when each drug has its own indication, but expect heart failure benefit rather than proven extra MACE or kidney protection.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month →

View on PubMed →

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!

Deep Analysis Pending

The full analysis for this article is being written and reviewed. Every analysis is checked by a licensed pharmacist before it publishes.